PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11806720-3 2002 Of this series, compound 7b (1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone) was found to exhibit the most potent and selective inhibition of peripheral COMT, with an inhibition profile more similar to entacapone 2 than tolcapone 1 (an equipotent peripheral and central inhibitor) but with much improved duration of action (7b, 70% inhibition and 2, 25% inhibition at 9 h after administration). Tolcapone 223-232 catechol-O-methyltransferase Rattus norvegicus 156-160 12111468-0 2002 Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro. Tolcapone 89-98 catechol-O-methyltransferase Rattus norvegicus 29-62 12111468-1 2002 Catechol-O-methyltransferase (COMT) inhibitors such as entacapone and tolcapone are used as adjuncts to L-DOPA ( l-3,4-dihydroxyphenylalanine, levodopa) in the treatment of Parkinson"s disease. Tolcapone 70-79 catechol-O-methyltransferase Rattus norvegicus 0-28 12111468-1 2002 Catechol-O-methyltransferase (COMT) inhibitors such as entacapone and tolcapone are used as adjuncts to L-DOPA ( l-3,4-dihydroxyphenylalanine, levodopa) in the treatment of Parkinson"s disease. Tolcapone 70-79 catechol-O-methyltransferase Rattus norvegicus 30-34 11942697-2 2002 Inhibition of catechol O-methyltransferase (COMT) with tolcapone led to increases in extracellular dopamine levels only when the baseline dopamine level was elevated by administration of L-3,4-dihydroxyphenylalanine in combination with the decarboxylation inhibitor carbidopa. Tolcapone 55-64 catechol-O-methyltransferase Rattus norvegicus 14-42 11942697-2 2002 Inhibition of catechol O-methyltransferase (COMT) with tolcapone led to increases in extracellular dopamine levels only when the baseline dopamine level was elevated by administration of L-3,4-dihydroxyphenylalanine in combination with the decarboxylation inhibitor carbidopa. Tolcapone 55-64 catechol-O-methyltransferase Rattus norvegicus 44-48 11942697-3 2002 Increases in dopamine levels in striatal dialysates by blockade of reuptake were enhanced by inhibition of metabolic degradation of dopamine by tolcapone, a selective catechol O-methyltransferase inhibitor. Tolcapone 144-153 catechol-O-methyltransferase Rattus norvegicus 167-195 11489299-4 2001 Tolcapone, a selective catechol-O-methyltransferase inhibitor, was used as a positive reference compound. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 23-51 11261749-9 2001 We conclude that the toxicological profile of the two COMT inhibitors, entacapone and tolcapone, differ from each other, tolcapone--unlike entacapone--showed hepatotoxicity. Tolcapone 121-130 catechol-O-methyltransferase Rattus norvegicus 54-58 11318939-1 2001 BACKGROUND: In recent years, several nitrocatechol derivatives (tolcapone, entacapone, and nitecapone) have been developed and found to be highly selective and potent inhibitors of catechol-O-methyltransferase (COMT). Tolcapone 64-73 catechol-O-methyltransferase Rattus norvegicus 181-209 11318939-1 2001 BACKGROUND: In recent years, several nitrocatechol derivatives (tolcapone, entacapone, and nitecapone) have been developed and found to be highly selective and potent inhibitors of catechol-O-methyltransferase (COMT). Tolcapone 64-73 catechol-O-methyltransferase Rattus norvegicus 211-215 11261749-1 2001 Entacapone and tolcapone are novel COMT (catechol-O-methyltransferase) inhibitors indicated for the adjunctive treatment of Parkinson"s disease (PD) in combination with levodopa. Tolcapone 15-24 catechol-O-methyltransferase Rattus norvegicus 35-39 11261749-1 2001 Entacapone and tolcapone are novel COMT (catechol-O-methyltransferase) inhibitors indicated for the adjunctive treatment of Parkinson"s disease (PD) in combination with levodopa. Tolcapone 15-24 catechol-O-methyltransferase Rattus norvegicus 41-69 11314772-0 2001 The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. Tolcapone 51-60 catechol-O-methyltransferase Rattus norvegicus 12-40 10323260-0 1999 Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Tolcapone 10-19 catechol-O-methyltransferase Rattus norvegicus 23-51 11081220-1 2000 Inhibition of catechol-0-methyltransferase (COMT) activity by Tolcapone was shown to result in increase of the striatal DA extracellular content in unrestrained rats pretreated with L-3,4-dihydroxyphenilalanine combined with Carbidopa, the decarboxylation inhibiting agent. Tolcapone 62-71 catechol-O-methyltransferase Rattus norvegicus 14-42 11081220-1 2000 Inhibition of catechol-0-methyltransferase (COMT) activity by Tolcapone was shown to result in increase of the striatal DA extracellular content in unrestrained rats pretreated with L-3,4-dihydroxyphenilalanine combined with Carbidopa, the decarboxylation inhibiting agent. Tolcapone 62-71 catechol-O-methyltransferase Rattus norvegicus 44-48 10323260-2 1999 Using microdialysis in freely moving rats, it was determined that combined administration of tolcapone with GBR 12909 resulted in a further increase of dopamine levels over that obtained without the catechol-O-methyltransferase inhibitor, while tolcapone alone failed to change dopamine levels. Tolcapone 93-102 catechol-O-methyltransferase Rattus norvegicus 199-227 9483396-1 1997 In vivo brain functions analysis was conducted to assess the effect of tolcapone, a novel catechol-O-methyltransferase (COMT) inhibitor on extracellular levels of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum of awake, freely moving eats during GBR 12909-induced blockade of DA uptake. Tolcapone 71-80 catechol-O-methyltransferase Rattus norvegicus 90-118 10064789-1 1999 The present study was aimed to evaluate the sensitivity of soluble (S) and membrane bound (MB) catechol-O-methyltransferase (COMT) from rat brain and liver to inhibitors which interact with the enzyme as competitive (tropolone), non-competitive (S-adenosyl-l-homocysteine; SAHC) and tight-binding (tolcapone and 3,5-dinitrocatechol) inhibitors. Tolcapone 298-307 catechol-O-methyltransferase Rattus norvegicus 125-129 10651109-4 1999 Therefore, the therapeutic action of tolcapone in Parkinson"s disease, might be dependent on the reduction of COMT activity in the extracerebral tissue. Tolcapone 37-46 catechol-O-methyltransferase Rattus norvegicus 110-114 9774242-3 1998 We wanted to determine whether the concentrations of free amine would be increased by catechol-O-methyltransferase inhibition with tolcapone and underpin the positive behavioural effects. Tolcapone 131-140 catechol-O-methyltransferase Rattus norvegicus 86-114 9460702-3 1998 In the present study, we analyzed levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in brain homogenates from rats which had received a one-week treatment with tolcapone or phenelzine, inhibitors of COMT and MAO, respectively. Tolcapone 180-189 catechol-O-methyltransferase Rattus norvegicus 219-223 10651109-2 1999 Here we report that a treatment of the cerebral tissue with tolcapone, a central and peripheral inhibitor of COMT, does not change the membrane responses of midbrain dopamine neurons to dopamine and levodopa. Tolcapone 60-69 catechol-O-methyltransferase Rattus norvegicus 109-113 9358559-8 1997 The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone > > entacapone > tolcapone; Vmax nitecapone > entacapone > tolcapone; Vmax/K(m) tolcapone > nitecapone > entacapone. Tolcapone 114-123 catechol-O-methyltransferase Rattus norvegicus 27-31 9358559-8 1997 The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone > > entacapone > tolcapone; Vmax nitecapone > entacapone > tolcapone; Vmax/K(m) tolcapone > nitecapone > entacapone. Tolcapone 162-171 catechol-O-methyltransferase Rattus norvegicus 27-31 9358559-8 1997 The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone > > entacapone > tolcapone; Vmax nitecapone > entacapone > tolcapone; Vmax/K(m) tolcapone > nitecapone > entacapone. Tolcapone 162-171 catechol-O-methyltransferase Rattus norvegicus 27-31 9483396-1 1997 In vivo brain functions analysis was conducted to assess the effect of tolcapone, a novel catechol-O-methyltransferase (COMT) inhibitor on extracellular levels of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum of awake, freely moving eats during GBR 12909-induced blockade of DA uptake. Tolcapone 71-80 catechol-O-methyltransferase Rattus norvegicus 120-124 8829199-0 1996 Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats. Tolcapone 16-25 catechol-O-methyltransferase Rattus norvegicus 29-57 9030401-0 1997 Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Tolcapone 39-48 catechol-O-methyltransferase Rattus norvegicus 0-28 9262345-0 1997 Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. Tolcapone 39-48 catechol-O-methyltransferase Rattus norvegicus 100-128 9262345-4 1997 In this study, we evaluated the kinetics of rat brain COMT, as well as its mechanisms of inhibition by tolcapone. Tolcapone 103-112 catechol-O-methyltransferase Rattus norvegicus 54-58 9262345-11 1997 In conclusion, our results show that tolcapone is a highly potent tight-binding inhibitor of brain soluble and membrane-bound COMT, but because of difficulties in determining the type of inhibition for this type of compound, we cannot confirm previous claims about the competitive type of COMT inhibition produced by tolcapone. Tolcapone 37-46 catechol-O-methyltransferase Rattus norvegicus 126-130 9262345-11 1997 In conclusion, our results show that tolcapone is a highly potent tight-binding inhibitor of brain soluble and membrane-bound COMT, but because of difficulties in determining the type of inhibition for this type of compound, we cannot confirm previous claims about the competitive type of COMT inhibition produced by tolcapone. Tolcapone 37-46 catechol-O-methyltransferase Rattus norvegicus 289-293 9141056-1 1997 The influence of tolcapone, an inhibitor of catechol-O-methyl transferase, was evaluated on the disposition of apomorphine, a dopamine agonist used to treat Parkinson"s disease, to explain a previously observed increase of duration of the effect of apomorphine associated with tolcapone. Tolcapone 17-26 catechol-O-methyltransferase Rattus norvegicus 44-73 8821542-0 1996 Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Tolcapone 82-91 catechol-O-methyltransferase Rattus norvegicus 38-66 8821542-10 1996 The sensitivity of liver and renal COMT activity to tolcapone was markedly dependent on the age, 3-days old rats being more sensitive to tolcapone than older animals. Tolcapone 52-61 catechol-O-methyltransferase Rattus norvegicus 35-39 8821542-10 1996 The sensitivity of liver and renal COMT activity to tolcapone was markedly dependent on the age, 3-days old rats being more sensitive to tolcapone than older animals. Tolcapone 137-146 catechol-O-methyltransferase Rattus norvegicus 35-39 8821542-11 1996 The IC50 values (in nM) for inhibition of liver COMT by tolcapone increased gradually with age, from 41 (26, 65) at the age of 3 days up to 720 (640, 800) at the age of 60 days. Tolcapone 56-65 catechol-O-methyltransferase Rattus norvegicus 48-52 8821542-12 1996 As was found in the liver, IC50 values (in nM) for inhibition of kidney COMT by tolcapone also increased with age, from 8 (6, 10) at the age of 3 days up to 177 (131, 240) at the age of 60 days. Tolcapone 80-89 catechol-O-methyltransferase Rattus norvegicus 72-76 8821542-13 1996 In all experimental groups, the IC50 values for inhibition of liver COMT by tolcapone was higher than those for kidney COMT. Tolcapone 76-85 catechol-O-methyltransferase Rattus norvegicus 68-72 8821542-16 1996 Furthermore, kidney COMT is shown to be more sensitive to inhibition by tolcapone than liver COMT, irrespective of the age of the animal. Tolcapone 72-81 catechol-O-methyltransferase Rattus norvegicus 20-24 8821542-2 1996 The present work describes the catechol-O-methyltransferase (COMT) activities in the liver and kidney of developing and adult rats (aged 3, 6, 9, 18, 30 and 60 days; n = 5 per group) and evaluates the enzyme sensitivity to inhibition by tolcapone, a reversible COMT inhibitor. Tolcapone 237-246 catechol-O-methyltransferase Rattus norvegicus 31-59 8821542-2 1996 The present work describes the catechol-O-methyltransferase (COMT) activities in the liver and kidney of developing and adult rats (aged 3, 6, 9, 18, 30 and 60 days; n = 5 per group) and evaluates the enzyme sensitivity to inhibition by tolcapone, a reversible COMT inhibitor. Tolcapone 237-246 catechol-O-methyltransferase Rattus norvegicus 61-65 7570359-8 1995 The monoamine oxidase inhibitor, pargyline (75 mg/kg), and the catechol-O-methyltransferase (COMT) inhibitor, Ro 40-7592 (40 mg/kg), had small or negligible effects in either region. Tolcapone 110-120 catechol-O-methyltransferase Rattus norvegicus 63-91 7737328-0 1995 Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Tolcapone 11-20 catechol-O-methyltransferase Rattus norvegicus 30-58 7674141-1 1995 The effect of Madopar (benserazide and L-dopa, 1:4) on the disposition of the new selective inhibitor of catechol-O-methyltransferase, tolcapone, in rats was investigated. Tolcapone 135-144 catechol-O-methyltransferase Rattus norvegicus 105-133 7737328-1 1995 In vivo brain microdialysis was used to assess the effects of tolcapone, a novel central and peripheral inhibitor of catechol-O-methyltransferase on striatal 3,4-dihydroxyphenyl-L-alanine (L-dopa) and dopamine metabolism. Tolcapone 62-71 catechol-O-methyltransferase Rattus norvegicus 117-145 7996385-5 1994 Tolcapone is a substrate for COMT although the 3-O-methylated metabolite produced has no pharmacological actions. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 29-33 7996385-7 1994 It is thought that the oral dose of tolcapone receives a high exposure to MB-COMT in the intestinal muscle layer during its absorption, and tolcapone seems to form a complex with MB-COMT having a high affinity constant (i.e. a very low Ki). Tolcapone 36-45 catechol-O-methyltransferase Rattus norvegicus 182-186 7996385-7 1994 It is thought that the oral dose of tolcapone receives a high exposure to MB-COMT in the intestinal muscle layer during its absorption, and tolcapone seems to form a complex with MB-COMT having a high affinity constant (i.e. a very low Ki). Tolcapone 140-149 catechol-O-methyltransferase Rattus norvegicus 182-186 7996385-7 1994 It is thought that the oral dose of tolcapone receives a high exposure to MB-COMT in the intestinal muscle layer during its absorption, and tolcapone seems to form a complex with MB-COMT having a high affinity constant (i.e. a very low Ki). Tolcapone 36-45 catechol-O-methyltransferase Rattus norvegicus 77-81 1628144-14 1992 Ro 40-7592 was a broad spectrum COMT inhibitor decreasing striatal and hypothalamic 3-OMD (always to less than 30%), HVA (to less than 50%) and 3-MT levels (to less than 23%) significantly both at 1 and 3 h. It was more potent than OR-611. Tolcapone 0-10 catechol-O-methyltransferase Rattus norvegicus 32-36 11224284-9 1994 These results suggest that selective, reversible COMT inhibitors such as tolcapone may offer an innovative approach to the treatment of depression, in addition to their potential therapeutic use in Parkinson"s disease. Tolcapone 73-82 catechol-O-methyltransferase Rattus norvegicus 49-53 1381981-1 1992 In vivo microdialysis was used to examine the effect of two new catechol-O-methyltransferase (COMT) inhibitors, Ro 40-7592 and OR-611, on extracellular levels of dopamine, dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA) in rat striatum. Tolcapone 112-122 catechol-O-methyltransferase Rattus norvegicus 94-98 8216760-6 1993 Pretreatment with Ro 40-7592, a catechol-O-methyltransferase inhibitor, potentiated and prolonged the anticataleptic effect of DOPS. Tolcapone 18-28 catechol-O-methyltransferase Rattus norvegicus 32-60 1383428-2 1992 Inhibitors of monoamine oxidase (MAO; pargyline) and catechol-O-methyltransferase (COMT; Ro 40-7592) were administered, either separately or in conjunction, at doses sufficient to block these enzymes in the CNS. Tolcapone 89-99 catechol-O-methyltransferase Rattus norvegicus 83-87 1613509-0 1992 Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. Tolcapone 152-162 catechol-O-methyltransferase Rattus norvegicus 113-141 1613509-1 1992 The effect of the systemic administration of a novel, orally active, catechol-O-methyltransferase (COMT) inhibitor, Ro 40-7592, on the in vivo extracellular concentrations of dopamine (DA) and its metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), was studied by transcerebral microdialysis in the dorsal caudate of freely moving rats. Tolcapone 116-126 catechol-O-methyltransferase Rattus norvegicus 69-97 1613509-1 1992 The effect of the systemic administration of a novel, orally active, catechol-O-methyltransferase (COMT) inhibitor, Ro 40-7592, on the in vivo extracellular concentrations of dopamine (DA) and its metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), was studied by transcerebral microdialysis in the dorsal caudate of freely moving rats. Tolcapone 116-126 catechol-O-methyltransferase Rattus norvegicus 99-103 1549240-1 1992 We administered Ro 40-7592, an inhibitor of the enzyme catechol-O-methyltransferase (COMT) that crosses the blood-brain barrier, to rats and monitored extracellular catecholamine levels in the corpus striatum before and after the intraperitoneal administration of a bolus of l-dopa. Tolcapone 16-26 catechol-O-methyltransferase Rattus norvegicus 55-83 1549240-1 1992 We administered Ro 40-7592, an inhibitor of the enzyme catechol-O-methyltransferase (COMT) that crosses the blood-brain barrier, to rats and monitored extracellular catecholamine levels in the corpus striatum before and after the intraperitoneal administration of a bolus of l-dopa. Tolcapone 16-26 catechol-O-methyltransferase Rattus norvegicus 85-89 2239490-0 1990 Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Tolcapone 0-10 catechol-O-methyltransferase Rattus norvegicus 65-93 2089102-0 1990 Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. Tolcapone 0-10 catechol-O-methyltransferase Rattus norvegicus 26-30 1977408-0 1990 Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson"s disease. Tolcapone 41-51 catechol-O-methyltransferase Rattus norvegicus 59-63 1977408-1 1990 Behavioural and some neurochemical effects of Ro 40-7592 (3,4-dihydroxy-4"-methyl-5-nitrobenzophenone), a new COMT inhibitor, were studied in rats and mice. Tolcapone 46-56 catechol-O-methyltransferase Rattus norvegicus 110-114 2089102-2 1990 Ro 40-7592 was found to inhibit COMT in a competitive fashion both in the CNS and in the periphery (Ki for the liver enzyme = 30 nM). Tolcapone 0-10 catechol-O-methyltransferase Rattus norvegicus 32-36 31491076-4 2019 Incubation of PC12 cells with tolcapone, a highly potent and selective COMT inhibitor, increased the concentrations of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) while reducing the metabolites 3-methoxytyramine (3-MT) and homovanillic acid (HVA) in the cell culture medium. Tolcapone 30-39 catechol-O-methyltransferase Rattus norvegicus 71-75 33289420-0 2021 Tissue and interspecies comparison of catechol-O-methyltransferase mediated catalysis of 6-O-methylation of esculetin to scopoletin and its inhibition by entacapone and tolcapone. Tolcapone 169-178 catechol-O-methyltransferase Rattus norvegicus 38-66 33289420-3 2021 Furthermore, we compared the inhibition potencies and mechanisms of two clinically used COMT inhibitors, entacapone and tolcapone, in these species. Tolcapone 120-129 catechol-O-methyltransferase Rattus norvegicus 88-92 33289420-9 2021 Both entacapone and tolcapone are potent COMT inhibitors, but their inhibition mechanisms differ. Tolcapone 20-29 catechol-O-methyltransferase Rattus norvegicus 41-45 32474681-7 2020 We benchmarked the performance of the novel COMT inhibitors to the effects produced by the known COMT inhibitor tolcapone. Tolcapone 112-121 catechol-O-methyltransferase Rattus norvegicus 44-48 32474681-7 2020 We benchmarked the performance of the novel COMT inhibitors to the effects produced by the known COMT inhibitor tolcapone. Tolcapone 112-121 catechol-O-methyltransferase Rattus norvegicus 97-101 31231499-0 2019 Catechol-o-methyltransferase inhibitor tolcapone improves learning and memory in naive but not in haloperidol challenged rats. Tolcapone 39-48 catechol-O-methyltransferase Rattus norvegicus 0-28 31231499-3 2019 Our aim was to assess the effect of COMT inhibitor tolcapone (TCP) on learning and memory in naive and haloperidol-challenged rats. Tolcapone 51-60 catechol-O-methyltransferase Rattus norvegicus 36-40 31231499-3 2019 Our aim was to assess the effect of COMT inhibitor tolcapone (TCP) on learning and memory in naive and haloperidol-challenged rats. Tolcapone 62-65 catechol-O-methyltransferase Rattus norvegicus 36-40 23613951-5 2013 Here, we investigated the effect of acute systemic administration of the brain-penetrant COMT inhibitor tolcapone on tissue levels of dopamine, noradrenaline, and the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Tolcapone 104-113 catechol-O-methyltransferase Rattus norvegicus 89-93 29310047-2 2018 In the current experiments, the COMT inhibitor tolcapone was utilized in an operant behavioral model of reinforcer-seeking and drinking to determine if this compound was capable of remediating the excessive seeking and drinking phenotype of the alcohol-preferring P rat. Tolcapone 47-56 catechol-O-methyltransferase Rattus norvegicus 32-36 29310047-11 2018 These data complement our previous findings in which tolcapone reduced cue-evoked responses in P rats and further suggest clinical utility of COMT inhibitors in the treatment of addiction disorders, specifically in male high drinkers. Tolcapone 53-62 catechol-O-methyltransferase Rattus norvegicus 142-146 27463695-1 2016 Recent efforts have been focused on the development of centrally active COMT inhibitors, which can be valuable assets for neurological disorders such as Parkinson"s disease, due to the severe hepatotoxicity risk associated with tolcapone. Tolcapone 228-237 catechol-O-methyltransferase Rattus norvegicus 72-76 24997271-6 2014 This conclusion was supported by an observation of higher concentration of l-DOPA in the incubation medium under perfusion of MBH with Krebs-Ringer solution containing tolcapone, an inhibitor of catechol-O-methyltransferase, and l-leucine than under perfusion with the same solution, but without l-leucine. Tolcapone 168-177 catechol-O-methyltransferase Rattus norvegicus 195-223 25257296-3 2014 METHODS: Working under the hypothesis that reductions in the bioavailability of DA play an integral role in the expression of the excessive drinking phenotype, the catechol-O-methyltransferase (COMT) inhibitor tolcapone was used as a means to amplify cortical DA concentration and drinking behaviors were then assessed. Tolcapone 210-219 catechol-O-methyltransferase Rattus norvegicus 164-192 25257296-3 2014 METHODS: Working under the hypothesis that reductions in the bioavailability of DA play an integral role in the expression of the excessive drinking phenotype, the catechol-O-methyltransferase (COMT) inhibitor tolcapone was used as a means to amplify cortical DA concentration and drinking behaviors were then assessed. Tolcapone 210-219 catechol-O-methyltransferase Rattus norvegicus 194-198 30406194-5 2018 On test days, the catechol-o-methyl-transferase (COMT) inhibitor tolcapone was administered prior to conditioning. Tolcapone 65-74 catechol-O-methyltransferase Rattus norvegicus 18-47 30406194-5 2018 On test days, the catechol-o-methyl-transferase (COMT) inhibitor tolcapone was administered prior to conditioning. Tolcapone 65-74 catechol-O-methyltransferase Rattus norvegicus 49-53 26919286-0 2016 Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Tolcapone 56-65 catechol-O-methyltransferase Rattus norvegicus 6-34 26919286-0 2016 Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Tolcapone 56-65 catechol-O-methyltransferase Rattus norvegicus 36-40 26919286-0 2016 Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Tolcapone 56-65 catechol-O-methyltransferase Rattus norvegicus 162-166 26919286-4 2016 A brain-penetrant COMT inhibitor, tolcapone, was tested in normal and phencyclidine-treated rats and COMT-Val transgenic mice. Tolcapone 34-43 catechol-O-methyltransferase Rattus norvegicus 18-22 25799918-4 2015 A selective dopamine D4 receptor agonist (A-412997) and the catechol-O-methyl-transferase (COMT) inhibitor; tolcapone, were investigated in the combined subtype of adult ADHD (ADHD-C). Tolcapone 108-117 catechol-O-methyltransferase Rattus norvegicus 91-95 24465516-7 2014 The methylation was reversed by tolcapone, a potent COMT inhibitor, in a dose-dependent manner. Tolcapone 32-41 catechol-O-methyltransferase Rattus norvegicus 52-56 23543593-0 2013 Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat. Tolcapone 24-33 catechol-O-methyltransferase Rattus norvegicus 14-18 23543593-6 2013 A 3-month treatment with tolcapone, a selective inhibitor of Comt, was carried out in PKD/Mhm and PKD/US (cy/+) animals. Tolcapone 25-34 catechol-O-methyltransferase Rattus norvegicus 61-65 23543593-10 2013 CONCLUSIONS: Comt has been confirmed to be the first reported modifier gene for PKD and tolcapone offers a promising drug for treating PKD. Tolcapone 88-97 catechol-O-methyltransferase Rattus norvegicus 13-17 23567203-3 2013 We used the COMT inhibitor, tolcapone, to assess the role of COMT activity in regulating the differential effects of the dopamine releaser, amphetamine (AMPH), on PPI in SD and LE rats. Tolcapone 28-37 catechol-O-methyltransferase Rattus norvegicus 12-16 23613951-13 2013 Furthermore, they suggest that the impact of tolcapone may be greater in females than males, a finding which may be of clinical significance in terms of the efficacy and dosing of COMT inhibitors. Tolcapone 45-54 catechol-O-methyltransferase Rattus norvegicus 180-184 19783845-3 2010 Tolcapone and entacapone are potent inhibitors of catechol-O-methyltransferase (COMT) for the treatment of Parkinson"s disease. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 50-78 20870159-6 2010 RESULTS: Treatment with the COMT inhibitor tolcapone was associated with a dose-dependent (EC(90) 5.3 +- 4.3 mg/kg) reduction in the lipophilic metabolite. Tolcapone 43-52 catechol-O-methyltransferase Rattus norvegicus 28-32 20870159-9 2010 CONCLUSIONS: Pre-treatment with the COMT inhibitor tolcapone inhibits formation of an interfering metabolite of R-[(11)C]SKF 82957. Tolcapone 51-60 catechol-O-methyltransferase Rattus norvegicus 36-40 19783845-3 2010 Tolcapone and entacapone are potent inhibitors of catechol-O-methyltransferase (COMT) for the treatment of Parkinson"s disease. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 80-84 15190105-2 2004 This study investigated the effect of tolcapone, a brain-penetrant COMT inhibitor, on a rat model of attentional set shifting, which is dependent on catecholamines and the medial PFC (mPFC). Tolcapone 38-47 catechol-O-methyltransferase Rattus norvegicus 67-71 19615953-0 2009 Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis. Tolcapone 85-94 catechol-O-methyltransferase Rattus norvegicus 45-74 19615953-3 2009 A method using mass spectrometry-based metabonomics combined with multivariate statistical analysis was applied to rapidly identify metabolite profiles of tolcapone, a catechol-O-methyl transferase inhibitor for Parkinson"s disease treatment. Tolcapone 155-164 catechol-O-methyltransferase Rattus norvegicus 168-197 15784340-1 2005 Aqueous solubility, apparent partition coefficient (logPapp) and catechol-O-methyltransferase (COMT, EC 2.1.1.6) inhibiting potency of entacapone and tolcapone were compared in vitro. Tolcapone 150-159 catechol-O-methyltransferase Rattus norvegicus 65-93 15784340-1 2005 Aqueous solubility, apparent partition coefficient (logPapp) and catechol-O-methyltransferase (COMT, EC 2.1.1.6) inhibiting potency of entacapone and tolcapone were compared in vitro. Tolcapone 150-159 catechol-O-methyltransferase Rattus norvegicus 95-99 15784340-6 2005 Entacapone and tolcapone inhibited equally rat striatal COMT in vitro with Ki values of 1.86 and 2.50 nM, respectively. Tolcapone 15-24 catechol-O-methyltransferase Rattus norvegicus 56-60 15784340-10 2005 In conclusion, entacapone and tolcapone are equally potent COMT inhibitors against rat striatal COMT in vitro. Tolcapone 30-39 catechol-O-methyltransferase Rattus norvegicus 59-63 15784340-10 2005 In conclusion, entacapone and tolcapone are equally potent COMT inhibitors against rat striatal COMT in vitro. Tolcapone 30-39 catechol-O-methyltransferase Rattus norvegicus 96-100 18854987-3 2009 As such, the beneficial cognitive effects of the COMT inhibitor tolcapone are postulated to be the result of increased bioavailability of DA in the PFC. Tolcapone 64-73 catechol-O-methyltransferase Rattus norvegicus 49-53 12538800-1 2003 Two catechol-O-methyltransferase (COMT) inhibitors, entacapone and tolcapone, were compared in the rat to elucidate the actual differences between their pharmacokinetics and pharmacodynamics after single and repeated administration. Tolcapone 67-76 catechol-O-methyltransferase Rattus norvegicus 34-38 12538800-5 2003 After a single oral dose (10 mg/kg), both entacapone and tolcapone produced an equal maximal degree of COMT inhibition in peripheral tissues, but tolcapone inhibited striatal COMT more effectively than did entacapone. Tolcapone 57-66 catechol-O-methyltransferase Rattus norvegicus 103-107 12538800-5 2003 After a single oral dose (10 mg/kg), both entacapone and tolcapone produced an equal maximal degree of COMT inhibition in peripheral tissues, but tolcapone inhibited striatal COMT more effectively than did entacapone. Tolcapone 146-155 catechol-O-methyltransferase Rattus norvegicus 175-179 12538800-7 2003 In tolcapone-treated animals, there was still extensive COMT inhibition present in peripheral tissues, and the degree of inhibition was higher than that attained after a single dose. Tolcapone 3-12 catechol-O-methyltransferase Rattus norvegicus 56-60 12538800-8 2003 The pharmacokinetic-pharmacodynamic modeling revealed that a plateau of COMT inhibition near the maximal attainable inhibition was reached already by plasma concentrations below 2000 ng/ml, both with entacapone and tolcapone. Tolcapone 215-224 catechol-O-methyltransferase Rattus norvegicus 72-76 12538800-9 2003 Entacapone and tolcapone inhibited equally rat liver COMT in vitro with K(i) values of 10.7 and 10.0 nM, respectively. Tolcapone 15-24 catechol-O-methyltransferase Rattus norvegicus 53-57 12538800-11 2003 The results also suggest that peripheral COMT is inhibited continuously when tolcapone is dosed at 12-h intervals, but this was not seen with entacapone. Tolcapone 77-86 catechol-O-methyltransferase Rattus norvegicus 41-45 12573869-1 2003 Tolcapone is a mixed (peripheral and central) catechol-O-methyltransferase (COMT) inhibitor, whereas entacapone is a preferential peripheral COMT inhibitor. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 46-74 12573869-1 2003 Tolcapone is a mixed (peripheral and central) catechol-O-methyltransferase (COMT) inhibitor, whereas entacapone is a preferential peripheral COMT inhibitor. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 76-80 12573869-3 2003 Tolcapone may also impair the extraneuronal catabolism of DA by inhibiting COMT activity in the brain. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 75-79 12573869-5 2003 Tolcapone and entacapone, at the dose of 15 mg/kg p.o., were almost equally effective in inhibiting COMT activity in duodenum and liver. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 100-104 12573869-6 2003 Tolcapone decreased striatal extracellular levels of homovanillic acid (HVA), thus confirming its central COMT inhibitory effect, whereas entacapone did not alter HVA efflux. Tolcapone 0-9 catechol-O-methyltransferase Rattus norvegicus 106-110 12393055-1 2002 Catechol-O-methyl transferase (COMT) inhibitors, entacapone and tolcapone, are used as an adjunctive treatment to L-dopa in Parkinson"s disease. Tolcapone 64-73 catechol-O-methyltransferase Rattus norvegicus 0-29 12393055-1 2002 Catechol-O-methyl transferase (COMT) inhibitors, entacapone and tolcapone, are used as an adjunctive treatment to L-dopa in Parkinson"s disease. Tolcapone 64-73 catechol-O-methyltransferase Rattus norvegicus 31-35 12454735-1 2002 The toxicity profiles of entacapone and tolcapone, novel catechol- O-methyl-transferase (COMT) inhibitors, have been reported to differ from each other. Tolcapone 40-49 catechol-O-methyltransferase Rattus norvegicus 57-87 12454735-1 2002 The toxicity profiles of entacapone and tolcapone, novel catechol- O-methyl-transferase (COMT) inhibitors, have been reported to differ from each other. Tolcapone 40-49 catechol-O-methyltransferase Rattus norvegicus 89-93 12180806-1 2002 Entacapone and tolcapone, novel catechol-O-methyl-transferase (COMT) inhibitors, have been developed for the treatment of Parkinson"s disease in combination with levodopa. Tolcapone 15-24 catechol-O-methyltransferase Rattus norvegicus 32-61 12180806-1 2002 Entacapone and tolcapone, novel catechol-O-methyl-transferase (COMT) inhibitors, have been developed for the treatment of Parkinson"s disease in combination with levodopa. Tolcapone 15-24 catechol-O-methyltransferase Rattus norvegicus 63-67